Aquestive Therapeutics, Inc. has made significant strides in its drug development efforts with the announcement that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film. This acceptance marks a crucial milestone for the company as it seeks to introduce a novel treatment for Type I allergic reactions, including anaphylaxis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, indicating when the agency plans to complete its review of the application.

The importance of this development cannot be overstated. Anaphylm, if approved, would be the first and only oral rescue medication for severe allergic reactions, providing a new treatment option for patients who currently have limited choices. The acceptance of the NDA resubmission is a positive signal for Aquestive, as it follows a previous Complete Response Letter from the FDA in January 2026, which requested additional data.

Background

Aquestive Therapeutics, Inc. operates in the pharmaceutical preparations sector, specifically focusing on innovative drug delivery technologies. The company is listed on the Nasdaq under the ticker symbol AQST and is headquartered in Warren, New Jersey. Recent filings indicate that Aquestive has been active in its regulatory processes, with the latest filing on October 15, 2026, being a pivotal moment in its drug development timeline.

What the Filing Says

The filing states, "On October 15, 2026, Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027." This statement highlights the FDA's classification of the resubmission as a Class 2 response, which typically indicates a more thorough review process.

Impact

This announcement may significantly impact patients at risk of anaphylaxis, as Anaphylm could provide a new, convenient treatment option. Additionally, the pharmaceutical industry may see increased competition in the allergy treatment market, particularly from companies developing similar innovative therapies. The successful approval of Anaphylm could also enhance Aquestive's market position and reputation as a leader in drug delivery technologies.

What's Next

The next steps for Aquestive Therapeutics will involve continuing to work closely with the FDA to complete the review of its NDA submission before the assigned goal date. The company is also advancing its commercial preparations to ensure readiness for a potential launch of Anaphylm, should it receive FDA approval.